Cutia Therapeutics
科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2487)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024

The Board is pleased to announce the unaudited consolidated interim results of the Group for the six months ended 30 June 2024, together with the comparative figures for the same period in 2023.

FINANCIAL HIGHLIGHTS

- Revenue increased by approximately 178.3% from approximately RMB34.3 million for the six months ended 30 June 2023 to approximately RMB95.6 million for the six months ended 30 June 2024.
- Gross profit margin increased by approximately 5 percentage points from approximately 48% for the six months ended 31 December 2023 to approximately 53% for the six months ended 30 June 2024.
- Adjusted net loss was approximately RMB161.0 million (non-IFRS adjustment) for the six months ended 30 June 2024. The Group continued to optimize its operating efficiency, and the proportion of adjusted net loss to revenue further narrowed.

BUSINESS HIGHLIGHTS

During the Reporting Period and up to the date of this announcement, we have made the following significant progress in advancing our product pipeline as well as business operations:

- **Commercialization:**
  - During the "618 campaign", total GMV of our scalp diseases and care products, and skin care products increased nearly five times year-over-year.
  - Sales volume of our scalp diseases and care products continued to increase and their performances were outstanding. Among them, CUP-MNDE ("Bailleul®" minoxidil spray) ranked Top 1 on Tmall Global in the category of dermatology drug for 16 consecutive months. Revenue from "HAIRGEOGRA®" selenium sulfide lotion grew 121 times year-over-year in the first half of 2024. In addition, the proportion of revenue from our scalp diseases and care products other than CUP-MNDE ("Bailleul®" minoxidil spray) continued to increase. OTC minoxidil liniment, a newly launched product of "HAIRGEOGRA®" in the first half of 2024, further improved our product portfolio. We were also dedicated in building long-term trust with consumers, the repurchase rate and conversion rate for customer service of the "HAIRGEOGRA®" flagship store on e-commerce platforms continued to be higher than the industry average.
  - Among our skin care products, "Phyto-C" O-Live series products accounted for more than 70% of the sales volume of our skin care products. We also expanded further into interest-based e-commerce channels, where its revenue contribution increased significantly year-over-year in the first half of 2024.

- **CU-40102 (topical finasteride spray):** CU-40102 is the first and only topical finasteride product approved for androgenetic alopecia treatment globally and the first topical finasteride to have its NDA accepted by the NMPA. The NDA of CU-40102 was accepted by the NMPA in January 2024 and the NDA was submitted to the Department of Health of the Government of Hong Kong in April 2024.

- **CU-10201(topical 4% minocycline foam):** CU-10201 is the first and only topical minocycline approved for acne vulgaris treatment globally and the first topical minocycline to have its NDA accepted by the NMPA. The indication of CU-10201 is for the treatment of non-nodular moderate to severe acne vulgaris in pediatric and adult patients aged nine years and older. CU-10201 was granted priority review designation by the CDE in August 2023 and the NDA was accepted by the NMPA in September 2023.

- **CU-30101 (localized topical lidocaine and tetracaine cream):** CU-30101 is a localized lidocaine and tetracaine compound topical anesthesia cream for surface dermatologic operations. Drug marketing authorization application for CU-30101 was accepted by the NMPA in July 2024.

- **CU-20401 (recombinant mutant collagenase):** We are conducting a Phase II clinical trial of CU-20401 for submental adipose accumulation in China to evaluate the efficacy and safety of CU-20401. The Phase II clinical trial has completed last patient enrollment in June 2024.

- **CU-10101 (topical novel small molecule agent):** CU-10101 is a non-hormonal, small molecule drug for the treatment of mild to moderate atopic dermatitis. The IND application of CU-10101 was approved by the CDE in May 2024.

- **Manufacturing facilities:** Cutia Wuxi, a wholly-owned subsidiary of the Company, has obtained the "Drug Manufacturing Certificate" issued by the Jiangsu Medical Products Administration in April 2024.

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

Founded in 2019, we are a R&D-driven, dermatology-focused biopharmaceutical company dedicated to developing comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. We have built a broad portfolio of products, targeting the four main sectors of the broader dermatology treatment and care market, namely scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication. We also distribute several commercialized products developed by overseas collaboration partners and marketed several products in China.

We are one of the few players in the broader dermatology treatment and care market in China equipped with fully integrated capabilities. We have applied a customer-centric approach to bolster our product candidates and expand our integrated capabilities to the entire broader dermatology treatment and care industry value chain. Our platform spans from the early phase of identifying demands, developing core technologies, managing clinical trials and product registrations, to the manufacturing and marketing of products.

Our proprietary CATAME® technology platform improves drugs to achieve topical or transdermal delivery by developing micron and nano-sized particulates, as well as evaluating formulation quality and stability, and performing cutaneous pharmacokinetic analysis. Our platform also helps design the most suitable product formats that are keys to specific and successful drug delivery. Through this platform, we have built a competitive product pipeline of creams, sprays, ointments, aerosol foams and other dosage forms.

BUSINESS REVIEW

As at the date of this announcement, we have achieved the following significant advancements in both pipeline products and business operations.

Scalp Diseases and Care

Key Product CU-40102 (topical finasteride spray)

– CU-40102 is the first and only topical finasteride product approved for androgenetic alopecia treatment globally and the first topical finasteride to have its NDA accepted by the NMPA. Finasteride can treat androgenetic alopecia in male patients by acting as a specific inhibitor of Type II 5-alpha reductase to inhibit the conversion of testosterone to DHT in the scalp.

– Unlike oral finasteride, CU-40102's topical formulation allows patients to apply the drug directly to the surface of the scalp, thereby maintaining a high concentration at the affected site while possibly reducing the side effects commonly associated with oral formulations.

– The NDA for CU-40102 was accepted by the NMPA in January 2024 and the NDA was submitted to the Department of Health of the Government of Hong Kong in April 2024.

Skin Diseases and Care

Key Product CU-10201 (topical 4% minocycline foam)

– CU-10201 is the first and only topical minocycline approved for acne vulgaris treatment globally and the first topical minocycline to have its NDA accepted by the NMPA. The indication of CU-10201 is for the treatment of non-nodular moderate to severe acne vulgaris in pediatric and adult patients aged nine years and older.

– Minocycline is a tetracycline antibiotic used to treat a number of bacterial infections and acne vulgaris. The currently available minocycline products are mostly oral medications. Compared to other major anti-acne antibiotics and conventional oral drugs, topical minocycline foam has lower systemic drug exposure, fewer side effects, lower rate of drug resistance, and likely higher patient compliance.

– CU-10201 was granted priority review designation by the CDE in August 2023 and the NDA was accepted by the NMPA in September 2023.

CU-10101 (topical novel small molecule agent)

– CU-10101 is a non-hormonal, small molecule drug for the treatment of mild to moderate atopic dermatitis. The non-hormonal properties of CU-10101 may reduce the side effects and restrictions associated with corticosteroids and its localized topical formulation allows the medication to reach the affected areas directly.

– The IND application of CU-10101 was accepted by the CDE in March 2024 and was approved by the CDE in May 2024.

Topical Anesthesia

CU-30101 (localized topical lidocaine and tetracaine cream)

– CU-30101 is a localized lidocaine and tetracaine compound topical anesthesia cream for surface dermatologic operations. The formulation of lidocaine and tetracaine combination in CU-30101 may produce rapid and long-lasting anesthetic effects due to its ingredients' unique pharmacokinetic properties.

– Lidocaine diffuses more rapidly, and more extensively than tetracaine, whereas tetracaine, a long-acting localized ester type anesthetic, is more lipophilic than lidocaine and can be concentrated in the topical stratum corneum. Systemic absorption of the anesthetic component ingredients is also limited from the topical cream formulation.

– The Phase III clinical trial of CU-30101 in China was completed in January 2024 and its drug marketing authorization application was accepted by the NMPA in July 2024.

Localized Adipose Accumulation Management Medication

***Core Product CU-20401* (recombinant mutant collagenase)**

– CU-20401 is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation associated metabolic diseases. CU-20401 adopts an alternative mechanism of action where it acts as a collagenase to selectively act on the extracellular matrix attached to adipose tissue. After localized injection, CU-20401 degrades extracellular matrix collagen in the subcutaneous fat layer which leads to apoptosis of adipocytes, and is expected to effectively reduce localized adipose accumulation.

– CU-20401 is technologically modified with reduced rate to catalyze the collagen degradation with mild catalytic activity, thus reducing the adverse effects of wild-type collagenase, such as bruising and pain.

– We are conducting a Phase II clinical trial of CU-20401 for submental adipose accumulation in China to evaluate the efficacy and safety of CU-20401. The Phase II clinical trial has completed last patient enrollment in June 2024. We expect to complete the Phase II clinical trial in 2025 and obtain regulatory approval for commercialization in China in 2028.

Warning: There is no assurance that the core product and each of the pipeline products will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

Commercialization

We have adopted a well-tailored commercialization strategy to penetrate the broader dermatology treatment and care market in China. Online marketing has always been one of our strategic priorities. Our dedicated marketing team has strong market insights and marketing capabilities, and is able to respond quickly to market changes. It continues to deliver excellent marketing output on various e-commerce platforms and social media platforms such as Tmall, JD, Bilibili, Douyin, Zhihu and Xiaohongshu. In addition, our self-operated customer service team provides customers with professional and suitable product support to optimize customer experience, increase repurchase rate and strengthen brand stickiness.

With strong product capabilities, sales and operational strengths, the Company has achieved outstanding performance in online sales. During the "618 campaign", total GMV of our scalp diseases and care products, and skin care products increased nearly five times year-over-year. Sales volume of our scalp diseases and care products continued to increase and their performances were outstanding. Among them, CUP-MNDE ("Bailleul®" minoxidil spray) ranked Top 1 on Tmall Global in the category of dermatology drug for 16 consecutive months. Revenue from "HAIRGEOGRA®" selenium sulfide lotion grew 121 times year-over-year in the first half of 2024. In addition, the proportion of revenue from our scalp diseases and care products other than CUP-MNDE ("Bailleul®" minoxidil spray) continued to increase. OTC minoxidil liniment, a newly launched product of "HAIRGEOGRA®" in the first half of 2024, further improved our product portfolio. We were also dedicated in building long-term trust with consumers, the repurchase rate and conversion rate for customer service of the "HAIRGEOGRA®" flagship store on e-commerce platforms continued to be higher than the industry average. Among our skin care products, "Phyto-C" O-Live series products accounted for more than 70% of the sales volume of our skin care products. We also expanded further into interest-based e-commerce channels, where their revenue contribution increased significantly year-over-year in the first half of 2024.

Our comprehensive commercialized product portfolio could address distinctive demands from a wide range of population groups as their needs evolve with disease progression or improvement to gain customer stickiness. Our products have features that are differentiated from other products in the market.

Manufacturing Facilities

Our commercial-scale GMP manufacturing facilities with three drug product production lines in Jiangsu Province has commenced operation in 2023. The three production lines cover topical cream, ointment, aerosol, and foam products. The flow and control of the entire manufacturing processes are designed to be compliant with the latest GMP requirements so that our production can meet the clinical and marketing approval requirements of various drug regulatory authorities, including the NMPA, FDA and European Medicines Agency. We believe the production capacity of this factory can support our clinical trials and near-term commercialization plans for our drug candidates.

In addition, Cutia Wuxi, a wholly-owned subsidiary of the Company, has obtained the "Drug Manufacturing Certificate" issued by the Jiangsu Medical Products Administration in April 2024, which is expected to play a long-term constructive role in production capacity expansion and market development of the Company, thus laying the foundation for subsequent commercialization of our product candidates.

KEY EVENTS AFTER THE REPORTING PERIOD

Subsequent to the Reporting Period, our drug candidate has made encouraging progress. For CU-30101, its drug marketing authorization application was accepted by the NMPA in July 2024. For more information, please refer to the announcement of the Company dated 31 July 2024.

We are delighted with the advancements we have made. Our R&D, medical and regulatory affairs teams will continue to work closely together to advance the clinical development of our product portfolio to prepare for the commercialization of our pipeline products.

FUTURE DEVELOPMENT

We are dedicated to providing consumers and patients with safe and comprehensive dermatology treatment and care solutions. Looking forward to the second half of 2024, we will continue to accelerate the clinical development of the products in our pipeline.

We are optimistic on the market potential of the online channels and will continue to adhere to our core marketing strategy of online marketing, while exploring into online-to-offline marketing combination. We will also continue to strengthen our sales capabilities and actively develop online marketing campaigns on various e-commerce platforms and social media platforms to increase brand awareness. In addition, we will work closely with renowned physicians to conduct product demonstrations and trainings.

Leveraging on our CATAME® technology platform, our integrated commercialization model, in-depth industry experience and the determination of our team, we believe we can seize the opportunities arising from the rapid expansion of China's sales network, provide innovative solutions for patients and generate higher returns to our Shareholders.

FINANCIAL REVIEW

Revenue

Our revenue was substantially generated from the sale of our in-licensed and distributed scalp diseases and care products and certain skin care products ("**Routine Skin Care Product**s") during the Reporting Period.

Revenue of the Group increased by 178.3% from RMB34.3 million for the six months ended 30 June 2023 to RMB95.6 million for the six months ended 30 June 2024, which was primarily due to an increase in sales of scalp diseases and care products and Routine Skin Care Products.

Cost of Sales

During the Reporting Period, our cost of sales primarily consisted of purchase costs and logistics costs related to our scalp diseases and care products, and Routine Skin Care Products. For the six months ended 30 June 2024, we recorded cost of sales of RMB45.2 million, representing an increase of RMB32.1 million from RMB13.1 million for the six months ended 30 June 2023. Such increase was in line with our business growth.

Gross Profit and Gross Profit Margin

Gross profit represents our revenue less our cost of sales. Gross profit margin represents our gross profit as a percentage of our revenue. Our gross profit amounted to RMB50.3 million for the six months ended 30 June 2024, representing an increase of 136.8% from RMB21.3 million for the six months ended 30 June 2023. Due to the change of product portfolio mix, our gross profit margin decreased from approximately 62% for the six months ended 30 June 2023 to approximately 53% for the corresponding period of 2024, but increased by approximately 5 percentage points from approximately 48% for the six months ended 31 December 2023.

Other Income and Gains

Our other income primarily consisted of interest income and government grants during the Reporting Period. The government grants mainly represent subsidies received from the PRC local government authorities during the Reporting Period for the purpose of compensating for our operating activities. Our interest income comprises (i) bank interest income; (ii) deemed interest income from loans to employees and related parties; and (iii) imputed interest income on rental and other deposits. Other income of the Group decreased by 44.6% from RMB21.5 million for the six months ended 30 June 2023 to RMB11.9 million for the six months ended 30 June 2024, which was primarily due to (i) a decrease in the receipt of the government grants from the PRC local government authorities to support certain operating activities during the Reporting Period; and (ii) a decrease in our bank interest income resulting from the decrease of our cash and cash equivalents and time deposits over three months.

During the Reporting Period, our gains primarily consisted of net foreign exchange gains which were in connection with our cash and cash equivalents and time deposits over three months denominated in the U.S. dollars, as a result of the appreciation of the U.S. dollar against RMB, and fair value gains on financial assets at fair value through profit or loss. Other gains decreased by 63.5% from RMB32.3 million for the six months ended 30 June 2023 to RMB11.8 million for the six months ended 30 June 2024, which was resulting from a smaller extent of the appreciation of the U.S. dollar against RMB during the Reporting Period as compared to the corresponding increase in 2023, and hence a decrease in the foreign exchange gains.

Selling and Distribution Expenses

During the Reporting Period, our selling and distribution expenses consisted of staff costs, share-based payments expenses, marketing expenses and others. Our selling and distribution expenses increased by 78.3% from RMB58.0 million for the six months ended 30 June 2023 to RMB103.5 million for the six months ended 30 June 2024, which was primarily due to an increase in staff costs and marketing expenses from the expansion in online marketing activities on e-commerce and social media platforms to further drive our online direct sales.

Research and Development Costs

During the Reporting Period, our research and development costs consisted of staff costs, share-based payment expenses, acquisition/licensing-in expenses, third-party contracting costs, depreciation and amortization and others. For the six months ended 30 June 2024, we recorded research and development costs of RMB99.0 million, representing an increase of 9.8% as compared to RMB90.1 million for the corresponding period of 2023, which was primarily due to (i) an increase in the number of our research and development personnel; and (ii) an increase in acquisition/licensing-in expenses in line with the achievement of key milestones.

Set out below are the components of research and development costs for the periods indicated:

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Staff costs	**27,802**	23,668
Share-based payment expenses	**11,809**	22,536
Acquisition/licensing-in expenses	**24,385**	943
Third-party contracting costs	**18,972**	26,641
Depreciation and amortization	**11,487**	11,930
Others	**4,553**	4,421
Total	**99,008**	90,139

Administrative Expenses

During the Reporting Period, our administrative expenses consisted of staff costs, share-based payment expenses, consulting fees, depreciation and amortization and others.

Administrative expenses decreased by 23.1% from RMB87.9 million for the six months ended 30 June 2023 to RMB67.6 million for the six months ended 30 June 2024, which was primarily due to the decrease in the share-based payment expenses resulting from the vesting of a portion of share options and restricted share units under the Pre-IPO Equity Incentive Plan.

Set out below are the components of administrative expenses for the periods indicated:

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Staff costs	**23,752**	24,596
Share-based payment expenses	**21,111**	39,849
Consulting fees	**7,943**	4,380
Depreciation and amortization	**7,153**	8,089
Others	**7,641**	11,020
Total	**67,600**	87,934

Finance Costs

During the Reporting Period, our finance costs mainly include interests on bank loans and lease liabilities. Finance costs increased by 182.4% from RMB1.7 million for the six months ended 30 June 2023 to RMB4.8 million for the six months ended 30 June 2024, which was primarily due to the increase in bank loans obtained to finance our daily operation.

Income Tax Expenses

Our income tax expense for the six months ended 30 June 2024 was nil (for the six months ended 30 June 2023: nil).

Fair Value Losses on Convertible Redeemable Preferred Shares

Our fair value losses on convertible redeemable preferred shares decreased from RMB1,454.3 million for the six months ended 30 June 2023 to nil for the corresponding period of 2024, due to the conversion of all of our convertible redeemable preferred shares upon listing.

Loss for the Period

As a result of the foregoing, we recorded a loss of RMB200.9 million for the six months ended 30 June 2024, representing a decrease of RMB1,439.4 million from a loss of RMB1,640.3 million for the six months ended 30 June 2023.

Non-IFRS Measures

To supplement our condensed consolidated financial statements which are presented in accordance with IFRS, we also use adjusted net loss for the period, a non-IFRS measure to present our operating performance. Adjusted net loss for the period, as an additional financial measure, is not required by, or presented in accordance with IFRS. We believe that such non-IFRS measure facilitates comparisons of our operating performance from period to period by eliminating impacts of non-cash or non-recurring items that our management considers to be not indicative of our operating performance and provides useful information to Shareholders and investors to evaluate our operating results in the same manner as our management does. However, our presentation of the adjusted net loss for the period may not be comparable to similarly titled measures presented by other companies. The use of such non-IFRS measure has limitations as an analytical tool, and Shareholders and investors should not consider it in isolation, or as substitute for analysis of, our results of operations or financial position as reported under IFRS. We define adjusted net loss for the period as loss for the period adjusted by adding back (i) fair value losses on convertible redeemable preferred shares; (ii) share-based payment expenses; and (iii) listing expenses. We continued to optimize its operating efficiency, and the proportion of adjusted net loss to revenue further narrowed.

The following table reconciles our non-IFRS adjusted net loss for the period with our loss for the periods indicated:

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss for the period	**(200,926)**	(1,640,339)
Add:		
Fair value losses on convertible redeemable preferred shares	**–**	1,454,280
Share-based payment expenses	**39,917**	72,687
Listing expenses	**–**	23,342
Non-IFRS adjusted net loss for the period	**(161,009)**	(90,030)
Proportion of non-IFRS adjusted net loss to revenue for the period	**(1.68)**	(2.62)

Liquidity and Financial Resources

As of 30 June 2024, our total cash and cash equivalents amounted to RMB276.0 million, representing a decrease of 41.7% as compared to RMB473.1 million as of 31 December 2023, which was primarily due to expenditures on research and development, selling and distribution and other operating activities.

As of 30 June 2024, our time deposits over three months amounted to RMB244.0 million, representing a decrease of 26.1% as compared to RMB330.2 million as of 31 December 2023, which was primarily in relation to the maturity of our time deposits.

As of 30 June 2024, our financial assets at fair value through profit or loss amounted to RMB519.1 million, representing an increase of 10.6% as compared to RMB469.3 million as of 31 December 2023, which was primarily due to the increase in our purchase of certain financial products to maximize return on capital.

As of 30 June 2024, our current assets amounted to RMB1,210.1 million, including cash and cash equivalents of RMB276.0 million. Our current liabilities amounted to RMB237.8 million, including interest-bearing bank borrowings of RMB170.3 million.

Indebtedness

The following table sets forth the breakdown of our lease liabilities and interest-bearing bank borrowings as of the dates indicated:

	As of 30 June 2024 ***RMB'000*** **(Unaudited)**	As of 31 December 2023 *RMB'000* (Audited)
Lease liabilities	**53,727**	54,344
Interest-bearing bank borrowings	**210,332**	189,411

Except as discussed above, we did not have any other material mortgages, charges, debentures, loan capital, debt securities, loans, bank overdrafts or other similar indebtedness, finance lease or hire purchase commitments, liabilities under acceptance (other than normal trade bills), acceptance credits, which are either guaranteed, unguaranteed, secured or unsecured, or guarantees or other contingent liabilities as of 30 June 2024.

Gearing Ratio

As of 30 June 2024, our gearing ratio was 21.2%, as compared with 21.0% as of 31 December 2023. Gearing ratio is calculated by dividing total liabilities by total assets and multiplying the product by 100%.

Significant Investments, Material Acquisitions and Disposal

We did not have any significant investments or material acquisitions or disposals of subsidiaries, associates and joint ventures for the six months ended 30 June 2024.

Capital Commitments

As of 30 June 2024, we had capital commitment of RMB20.1 million for the contracts in relation to acquisition of property, plant and equipment and other intangible assets (as of 31 December 2023: RMB3.2 million).

Contingent Liabilities

As of 30 June 2024, we did not have any material contingent liabilities, guarantees or any litigation against us (as of 31 December 2023: nil).

Pledge of Assets

As of 30 June 2024, we did not pledged or charged any assets (as of 31 December 2023: nil).

Foreign Exchange Exposure

Foreign currency risk refers to the risk of loss resulting from changes in foreign currency exchange rates. Fluctuations in exchange rates between RMB and other currencies in which the Group conducts business may affect our financial condition and results of operation. The Group mainly operates in the PRC and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to Hong Kong dollars and the U.S. dollars. The conversion of foreign currencies into RMB, including Hong Kong dollars and the U.S. dollars, has been based on rates set by the People's Bank of China. The Group primarily limits our exposure to foreign currency risk by closely monitoring the foreign exchange market. For the six months ended 30 June 2024, the Group did not enter into any currency hedging transactions.

Use of Proceeds

The Group received net proceeds (after deduction of underwriting commissions and related costs and expenses) from the global offering of approximately HK$392.7 million (equivalent to approximately RMB356.8 million). As of 30 June 2024, such net proceeds were utilized as follows:

Use of proceeds from the listing	Amount of net proceeds for planned applications *(HK$ million)*	Percentage of total net proceeds *(%)*	Unutilized net proceeds as at 1 January 2024 *(HK$ million)*	Utilized net proceeds during the Reporting Period *(HK$ million)*	Unutilized net proceeds as of 30 June 2024 *(HK$ million)*	Expected time frame for unutilized amount
For the Core Product						
1. For funding the costs and expenses in connection with R&D personnel as well as continuing R&D activities of CU-20401	164.9	42.0%	147.3	1.7	145.6	by the end of 2029
2. For the local production of CU-20401 in Chinese Mainland	11.8	3.0%	11.8	–	11.8	by the end of 2029
For the Key Products						
1. For funding the costs and expenses in connection with R&D personnel as well as continuing R&D activities of CU-40102 and CU-10201	43.2	11.0%	15.8	1.7	14.1	by the end of 2026
2. For milestone payments of CU-10201	43.2	11.0%	43.2	–	43.2	by the end of 2026
For the other candidates in the pipeline						
1. For the continuing R&D activities of CU-40101, CU-40103, CU-40104 and other potential scalp diseases and care products	28.3	7.2%	10.6	1.3	9.3	by the end of 2028
2. For the continuing R&D activities of CU-10101, CU-10401 and other potential skin diseases and care products	28.3	7.2%	19.1	0.8	18.3	by the end of 2028
3. For the continuing R&D activities of CU-30101	14.1	3.6%	–	–	–	
For technology development and business development for pipeline expansion	**39.3**	**10.0%**	**14.7**	**–**	**14.7**	**by the end of 2025**
For our working capital and other general corporate purposes	**19.6**	**5.0%**	**–**	**–**	**–**	
Total	**392.7**	**100.0%**	**262.5**	**5.5**	**257.0**	

Employees and Remuneration

As of 30 June 2024, the Group had a total of 360 employees. The total remuneration cost of the Group for the six months ended 30 June 2024 was RMB113.7 million, as compared to RMB134.4 million for the six months ended 30 June 2023, which was primarily due to the decrease in share-based payment expenses. The following table sets forth the total number of employees by function as of 30 June 2024:

Function	Number	Percentage of total
R&D	50	13.9%
Manufacturing and Quality Control	57	15.8%
Medical and Regulatory Affairs	47	13.1%
Sales, Marketing and Administration	206	57.2%
Total	360	100.0%

The remuneration of the employees of the Group comprises salaries, bonuses, employees' provident fund, share-based payment, social security contributions and other welfare payments. In accordance with applicable laws and regulations, we made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for the Group's employees.

OTHER INFORMATION

Compliance with the Corporate Governance Code

The Company has adopted the principles and code provisions in the Corporate Governance Code and has complied with all applicable code provisions for the six months ended 30 June 2024.

Model Code for Securities Transactions

The Company has adopted the Model Code as its own code of conduct regarding securities transactions by the Directors. Having made specific enquiries with all Directors, each of them has confirmed that he/she has complied with the Model Code during the six months ended 30 June 2024. No incident of non-compliance of the Model Code by the employees who are likely to be in possession of inside information was noted by the Company.

Purchase, Sale or Redemption of Listed Securities

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares) for the six months ended 30 June 2024.

Subsequent to 30 June 2024 and up to the date of this announcement, the Company had repurchased a total of 585,800 Shares of the Company (the "**Repurchased Shares**") on the Stock Exchange (the "**Share Repurchase**"). The aggregate purchase price paid for the Repurchased Shares was approximately HK$4.2 million. The Repurchased Shares represented approximately 0.19223% of the issued shares (excluding treasury shares) as at the date of the resolution granting the repurchase mandate.

Details of the Repurchased Shares are as follows:

Month of repurchase	**Events**	**Number of shares repurchased**	**Highest repurchase price per share** *(HK$)*	**Lowest repurchase price per share** *(HK$)*	**Aggregate price paid** *(HK$)*
2024					
July	Repurchase of shares (shares held as treasury shares)	585,800	7.6	6.93	4,207,186.4
Total		585,800			4,207,186.4

Subsequent to the Share Repurchase, the Repurchased Shares were accounted for as treasury shares and the total number of issued shares of the Company remain unchanged at 304,738,625 shares.

REVIEW OF FINANCIAL INFORMATION

Audit Committee

The Board has established the Audit Committee which comprises Mr. Chung Ming Kit (chairman), Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang, who are all our independent non-executive Directors. The primary duties of the Audit Committee are to review and supervise the Company's financial reporting process, risk management and internal controls.

The Audit Committee, together with the management of the Company, has reviewed the accounting principles and practices adopted by the Group and discussed risk management, internal control and financial reporting matters with management including a review of the unaudited interim condensed consolidated financial information of the Group for the six months ended 30 June 2024.

Scope of Work of Ernst & Young

The Company's external auditor, Ernst & Young, has performed an independent review of the Group's interim financial information for the Reporting Period in accordance with Hong Kong Standard on Review Engagement 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants.

Interim Dividend

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2024 (30 June 2023: nil).

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.cutiatx.com).

The interim report of the Company for the six months ended 30 June 2024 containing all the information required by the Listing Rules will be made available to the Shareholders and will be published on the respective websites of the Stock Exchange and the Company in due course.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2024

	Notes	**2024** ***RMB'000*** **(Unaudited)**	2023 *RMB'000* (Unaudited)
Revenue	*4*	**95,575**	34,343
Cost of sales		**(45,240)**	(13,083)
Gross profit		**50,335**	21,260
Other income and gains	*4*	**23,707**	53,844
Selling and distribution expenses		**(103,486)**	(58,032)
Research and development costs		**(99,008)**	(90,139)
Administrative expenses		**(67,600)**	(87,934)
Fair value losses on convertible redeemable preferred shares		**–**	(1,454,280)
Other expenses		**(28)**	–
Finance costs		**(4,846)**	(1,716)
Listing expenses		**–**	(23,342)
LOSS BEFORE TAX		**(200,926)**	(1,640,339)
Income tax expense	*5*	**–**	–
LOSS AND TOTAL COMPREHENSIVE LOSS FOR THE PERIOD		**(200,926)**	(1,640,339)
Attributable to:			
Owners of the parent		**(200,926)**	(1,640,339)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT			
Basic and diluted (RMB)	*7*	**(0.66)**	(15.84)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2024

	Notes	**30 June 2024** ***RMB'000*** **(Unaudited)**	31 December 2023 *RMB'000* (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment		**176,392**	177,664
Right-of-use assets		**46,970**	48,344
Other intangible assets		**8,204**	7,810
Amounts due from related parties		**36,462**	36,494
Prepayments, other receivables and other assets		**29,648**	20,169
Total non-current assets		**297,676**	290,481
CURRENT ASSETS			
Inventories		**64,722**	45,314
Trade receivables	*8*	**53,309**	62,198
Prepayments, other receivables and other assets		**51,645**	34,855
Amounts due from related parties		**1,332**	1,300
Financial assets at fair value through profit or loss ("**FVTPL**")	*9*	**519,087**	469,337
Time deposits over three months		**243,959**	330,192
Cash and cash equivalents		**276,047**	473,120
Total current assets		**1,210,101**	1,416,316

	Notes	30 June 2024 *RMB'000* (Unaudited)	31 December 2023 *RMB'000* (Audited)
CURRENT LIABILITIES			
Trade and other payables	*10*	**55,385**	113,603
Lease liabilities		**12,060**	11,374
Deferred income		**–**	400
Interest-bearing bank borrowings	*11*	**170,332**	129,411
Total current liabilities		**237,777**	254,788
NET CURRENT ASSETS		**972,324**	1,161,528
TOTAL ASSETS LESS CURRENT LIABILITIES		**1,270,000**	1,452,009
NON-CURRENT LIABILITIES			
Lease liabilities		**41,667**	42,970
Interest-bearing bank borrowings	*11*	**40,000**	60,000
Total non-current liabilities		**81,667**	102,970
Net assets		**1,188,333**	1,349,039
EQUITY			
Equity attributable to owners of the parent			
Share capital		**43**	43
Reserves		**1,188,290**	1,348,996
Total equity		**1,188,333**	1,349,039

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

1. CORPORATE INFORMATION AND BASIS OF PREPARATION

1.1 Corporate information

Cutia Therapeutics (the "**Company**") was incorporated in the Cayman Islands as an exempted company with limited liability on 15 May 2019, and its shares are listed on The Stock Exchange of Hong Kong Limited on 12 June 2023. The registered office address of the Company is 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands.

The Company is an investment holding company. The Company and its subsidiaries (the "**Group**") are principally engaged in developing innovative and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market.

1.2 Basis of preparation

The interim condensed consolidated financial information for the six months ended 30 June 2024 has been prepared in accordance with International Accounting Standard 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2023.

This interim condensed consolidated financial information is presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand except when otherwise indicated.

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2023, except for the adoption of the following revised International Financial Reporting Standards ("**IFRSs**") for the first time for the current period's financial information.

Amendments to IFRS 16	*Lease Liability in a Sale and Leaseback*
Amendments to IAS 1	*Classification of Liabilities as Current or Non-current* (the "**2020 Amendments**")
Amendments to IAS 1	*Non-current Liabilities with Covenants* (the "**2022 Amendments**")
Amendments to IAS 7 and IFRS 7	*Supplier Finance Arrangements*

The nature and impact of the revised IFRSs are described below:

(a) Amendments to IFRS 16 specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains. Since the Group has no sale and leaseback transactions with variable lease payments that do not depend on an index or a rate occurring from the date of initial application of IFRS 16, the amendments did not have any impact on the financial position or performance of the Group.

(b) The 2020 Amendments clarify the requirements for classifying liabilities as current or non-current, including what is meant by a right to defer settlement and that a right to defer must exist at the end of the reporting period. Classification of a liability is unaffected by the likelihood that the entity will exercise its right to defer settlement. The amendments also clarify that a liability can be settled in its own equity instruments, and that only if a conversion option in a convertible liability is itself accounted for as an equity instrument would the terms of a liability not impact its classification. The 2022 Amendments further clarify that, among covenants of a liability arising from a loan arrangement, only those with which an entity must comply on or before the reporting date affect the classification of that liability as current or non-current. Additional disclosures are required for non-current liabilities that are subject to the entity complying with future covenants within 12 months after the reporting period.

The Group has reassessed the terms and conditions of its liabilities as at 1 January 2023 and 2024 and concluded that the classification of its liabilities as current or non-current remained unchanged upon initial application of the amendments. Accordingly, the amendments did not have any impact on the financial position or performance of the Group.

(c) Amendments to IAS 7 and IFRS 7 clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk. The disclosure of relevant information for supplier finance arrangements is not required for any interim reporting period during the first annual reporting period in which an entity applies the amendments. As the Group does not have supplier finance arrangements, the amendments did not have any impact on the interim condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

Operating segment information

For management purposes, the Group has only one reportable operating segment, which is developing innovative and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. Since this is the only reportable operating segment of the Group, no further operating segment analysis thereof is presented.

Geographical information

During the Reporting Period, all of the Group's revenue was derived from customers located in the People's Republic of China ("**PRC**") and nearly all of the Group's non-current assets were located in the PRC, and therefore no geographical segment information is presented in accordance with IFRS 8 *Operation Segments*.

Information about major customers

Revenue derived from sales to customers, which amounted to more than 10% of the Group's revenue during the six months ended 30 June 2024 and 2023, is as follows:

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Customer A	**21,307**	–
Customer B	**12,711**	13,344

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue from contracts with customers		
Sale of products – at a point in time	**95,575**	34,343

An analysis of other income and gains is as follows:

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Other income		
Government grants*	**3,739**	7,855
Bank interest income	**6,326**	12,057
Imputed interest income on rental and other deposits	**247**	84
Deemed interest income from loans to employees	**128**	114
Deemed interest income from the loans to related parties	**650**	610
Others	**819**	785
Total other income	**11,909**	21,505
Gains		
Foreign exchange gains, net	**1,234**	27,680
Gain on termination of a lease contract	**–**	37
Fair value gains on financial assets at FVTPL	**10,564**	4,622
Total gains	**11,798**	32,339
Total other income and gains	**23,707**	53,844

* The government grants have been received from the PRC local government authorities to support certain subsidiaries' operating activities. There are no unfulfilled conditions relating to these government grants.

5. INCOME TAX

The Company was incorporated in the Cayman Islands and is exempted from income tax.

No Hong Kong profits tax was provided for as there was no estimated assessable profit of the Group's Hong Kong subsidiary that was subject to Hong Kong profits tax during the periods presented in the interim condensed consolidated financial information.

No PRC Enterprise Income tax was provided for as there was no estimated assessable profit of the Group's PRC subsidiaries during the periods presented in the interim condensed consolidated financial information.

Deferred taxation had not been fully recognised on the unused tax losses and deductible temporary differences since it is not probable that the taxable profits will be available against which the tax losses and deductible temporary differences can be utilised in the foreseeable future.

6. DIVIDENDS

No dividend was paid or proposed for ordinary shareholders of the Company during the six months ended 30 June 2024, nor has any dividend been proposed since the end of the Reporting Period (during the six months ended 30 June 2023: nil).

7. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amounts for the six months ended 30 June 2024 and 2023 is based on the loss for the period attributable to ordinary equity holders of the parent and the weighted average numbers of ordinary shares in issue.

The weighted average number of ordinary shares for the purpose of calculating basic and diluted earnings per share for the six months ended 30 June 2023 has been retrospectively adjusted for the effect of the Share Subdivision.

No adjustment has been made to the basic loss per share amounts presented for the six months ended 30 June 2024 in respect of a dilution as the impact of share options and restricted share units had an anti-dilutive effect on the basic loss per share amounts presented. No adjustment has been made to the basic loss per share amounts presented for the six months ended 30 June 2023 in respect of a dilution as the impact of convertible redeemable preferred shares, over-allocation option, share options and restricted share units had an anti-dilutive effect on the basic loss per share amounts presented.

The calculations of basic and diluted loss per share are based on:

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss		
Loss attributable to ordinary equity holders of the parent for the purpose of calculating basic and diluted loss per share (RMB'000)	**(200,926)**	(1,640,339)
Shares		
Weighted average number of ordinary shares in issue during the period used in the basic and diluted loss per share calculation	**304,730,777**	103,557,292
Loss per share (basic and diluted) (RMB per share)	**(0.66)**	(15.84)

8. TRADE RECEIVABLES

An ageing analysis of the trade receivables as at the end of the Reporting Period, based on the invoice date and net of loss allowance, is as follows:

	30 June	31 December
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 1 month	**27,515**	21,268
1 month to 6 months	**24,142**	40,824
6 months to 12 months	**1,652**	106
Total	**53,309**	62,198

9. FINANCIAL ASSETS AT FVTPL

	30 June 2024	31 December 2023
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Financial products	**519,087**	469,337

The financial assets measured at FVTPL represented financial products with no predetermined return which are principal protected investments. The financial products are with expected yield rates, depending on the market prices of underlying financial instruments, including bonds, debentures and other financial assets. Hence their contractual cash flows do not qualify for solely payments of principal and interest. The expected yield rates ranged from 1.5% to 4.5% per annum as at 30 June 2024 (31 December 2023: 1.5% to 4.5% per annum).

10. TRADE AND OTHER PAYABLES

	30 June 2024	31 December 2023
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade payables	**4,657**	20,292
Accrued expenses for research and development services	**14,369**	23,105
Payables for purchase of items of property, plant and equipment	**5,476**	3,454
Other payables	**16,656**	41,208
Salary and bonus payables	**6,659**	11,735
Other taxes payable	**1,034**	1,342
Accrued listing expenses	**6,534**	12,467
Total	**55,385**	113,603

An ageing analysis of the trade payables as at the end of each of the Reporting Period, based on the invoice date, is as follows:

	30 June 2024	31 December 2023
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 3 months	**4,657**	20,292

11. INTEREST-BEARING BANK BORROWINGS

	30 June 2024			31 December 2023		
	Effective interest rate (%)	**Maturity**	**Amount *RMB'000* (Unaudited)**	Effective interest rate (%)	Maturity	Amount *RMB'000* (Audited)
Current						
Bank loans – unsecured	**3.05**	**2025**	**9,900**	–	–	–
Bank loans – unsecured	**2.95**	**2025**	**39,600**	–	–	–
Bank loans – unsecured	**3.21**	**2025**	**9,903**	–	–	–
Bank loans – unsecured	**2.73**	**2025**	**11,732**	–	–	–
Bank loans – unsecured	**2.85**	**2025**	**49,288**	–	–	–
Bank loans – unsecured	**3.55**	**2024**	**9,909**	3.55	2024	9,900
Bank loans – unsecured	**–**	**–**	**–**	3.65	2024	69,361
Bank loans – unsecured	**–**	**–**	**–**	3.19	2024	10,150
Current portion of long term bank loans – secured (note)	**3.45**	**2024-2025**	**40,000**	3.45	2024	40,000
Total – current			**170,332**			129,411
Non-current						
Other secured bank loans (note)	**3.45**	**2025-2026**	**40,000**	3.45	2025-2026	60,000
Total – non-current			**40,000**			60,000
Total			**210,332**			189,411

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Analysed into:		
Bank loans repayable:		
Within one year or on demand	**170,332**	129,411
In the second year	**40,000**	40,000
In the third to fifth years, inclusive	**–**	20,000
Total	**210,332**	189,411

The carrying amounts of borrowings are denominated in the following currency:

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
RMB	**210,332**	189,411

An analysis of the carrying amounts of borrowings by type of interest rate is as follows:

	30 June 2024 RMB'000 (Unaudited)	31 December 2023 RMB'000 (Audited)
Fixed interest rate	**210,332**	189,411

Note: The Company has guaranteed certain of the Group's bank loans up to RMB120,000,000 as at the end of the Reporting Period.

"androgenetic alopecia"	a common form of hair loss in both men and women
"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors of our Company
"CDE"	Center for Drug Evaluation of the NMPA (中國國家藥品監督管理局藥品審評中心), a division of the NMPA to review applications for clinical trials and drug marketing authorization
"China", "Chinese Mainland", or "PRC"	the People's Republic of China, but for the purpose of this announcement and for geographical reference only and except where the context requires, excluding Taiwan, the Macao Special Administrative Region and Hong Kong
"clinical trial(s)"	a research study for validating or finding the therapeutic effects and side effects of test drugs in order to determine the therapeutic value and safety of such drugs
"Company"	Cutia Therapeutics (科笛集團), an exempted company with limited liability incorporated under the laws of the Cayman Islands on 15 May 2019, the Shares of which are listed on the Main Board of the Stock Exchange (stock code: 2487)
"Core Product"	has the meaning ascribed to it under Chapter 18A of the Listing Rules; for the purpose of this announcement, our Core Product refers to CU-20401
"Corporate Governance Code"	the Corporate Governance Code contained in Appendix C1 to the Listing Rules
"Cutia Wuxi"	Cutia Therapeutics (Wuxi) Co., Ltd. (科笛生物醫藥(無錫)有限公司), a limited liability company established in the PRC on 4 December 2020 and a wholly-owned subsidiary of the Company
"dermatology"	the branch of medicine that deals with the diagnosis and treatment of skin related disorders
"DHT"	dihydrotestosterone, a male sex hormone which is the active form of testosterone, formed from testosterone in bodily tissue
"Director(s)"	the director(s) of the Company
"FDA"	Food and Drug Administration of the United States
"GMP"	good manufacturing practice, the practices required in order to conform to the guidelines recommended by agencies that control the authorization and licensing of the manufacture and sale of products

"GMV"	gross merchandise value
"Group", "our Group", "our", "we", or "us"	our Company and our subsidiaries
"HK$" or "Hong Kong Dollars"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong" or "HK"	the Hong Kong Special Administrative Region of the PRC
"IFRS"	International Financial Reporting Standards
"IND"	investigational new drug, an application in the drug review process required by an regulatory authority to decide whether a new drug is permitted to initiate clinical trials; also known as clinical trial application, or CTA, in China
"indication"	a valid reason to use a specific test, drug, device, procedure or surgery
"Key Product"	for the purpose of this announcement, our Key Products refer to CU-40102 and CU-10201
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
"mechanism of action"	the specific biochemical interaction through which a drug substance produces its pharmacological effect
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
"NDA"	new drug application, a process required by an regulatory authority to approve a new drug for sale and marketing
"NMPA"	the National Medical Products Administration of China (中國國家藥品監督管理局)
"OTC"	over-the-counter, a kind of drug that may be sold over the counter upon receiving the competent authority's approval at dispensers, pharmacies or retail outlets without requiring a prescription by a medical practitioner
"Phase I clinical trial"	a study in which a drug is introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and if possible, to gain an early indication of its efficacy

"Phase II clinical trial"	a study in which a drug is administered to a limited patient population to preliminarily evaluate the efficacy of the product for specific targeted diseases, to identify possible adverse effects and safety risks, and to determine optimal dosage
"Phase III clinical trial"	a study in which a drug is administered to an expanded patient population generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to provide adequate information for the labeling of the product
"R&D"	research and development
"Reporting Period"	the six months ended 30 June 2024
"RMB"	the lawful currency of the PRC
"Shares"	ordinary share(s) with nominal value of US$0.00002 each in the share capital of the Company
"Shareholders"	holder(s) of the Shares
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed to it in section 15 of the Companies Ordinance
"US" or "United States" or "the U.S."	the United States of America, its territories and possessions, any State of the United States, and the District of Columbia
"US$" or "U.S. dollars"	the lawful currency of the U.S.

By order of the Board
Cutia Therapeutics
Zhang Lele
Chief Executive Officer and Executive Director

Hong Kong, 29 August 2024

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive Directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao and Ms. Yang Yunxia as non-executive Directors; and (iii) Mr. Chung Ming Kit, Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang as independent non-executive Directors.